iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
iBio (NASDAQ: IBIO) reported preclinical obese NHP results for its single-dose Activin E antibody IBIO-610. Active Activin E was suppressed in all treated animals through eight weeks, with ~98% reduction at week 4 and ~97% at week 8. In combination with semaglutide, IBIO-610 increased visceral/total fat loss and cut lean-mass loss by 73% versus semaglutide alone; full data will be presented at EASD 2026.
How this was made
The 30-second read
Why it matters
The company claims near-complete suppression of active Activin E for eight weeks after a single dose and, when combined with semaglutide, improved fat loss with reduced lean-mass loss versus semaglutide alone.
Market read
This is a fresh preclinical dataset that may support IBIO-610’s differentiation (durability and fat-selective weight loss), but it is not yet a clinical proof point.
What to watch
The release provides target engagement and composition comparisons but no dosing regimen details, sample sizes, or translational biomarkers that would de-risk human outcomes.
Background
iBio is developing IBIO-610, a long-acting antibody targeting Activin E, for obesity and related cardiometabolic indications.
Ticker impact
iBio reported preclinical obese NHP results showing a single IBIO-610 dose suppressed active Activin E by ~97–98% through eight weeks.
Near-term sentiment tailwind for IBIO, but likely limited follow-through until human efficacy/safety data or trial readouts arrive.
This is preclinical NHP evidence with strong target engagement and body-composition signals, but it is not a clinical endpoint or regulatory event.
Market effects
Reinforces the obesity pipeline narrative that durable, body-composition-focused antibodies may complement or differentiate from GLP-1 therapies.
No clear regional market linkage beyond general US biotech risk appetite.
EASD conference timing may influence global obesity-biotech attention, but the findings are preclinical.
Counterpoint
Strong Activin E inhibition in NHPs may not translate to human efficacy, durability, or safety; body-composition benefits could diminish in clinical settings.
Key entities
- companyiBio, Inc.
Clinical-stage biotech developing long-acting antibody therapeutics; subject of the press release.
- drug_candidateIBIO-610
Activin E antibody candidate evaluated in obese non-human primates.
- biomarker_targetActivin E
Pathway target; active levels were suppressed ~97–98% through eight weeks in treated NHPs.
- comparatorSemaglutide
GLP-1 therapy used in combination to assess body-composition effects in the NHP study.
- eventEASD Annual Meeting 2026
Conference where the full dataset will be presented (Sept. 28–Oct. 2, Milan).
